GM-CSF-secreting melanoma vaccinesDRANOFF, Glenn.Oncogene (Basingstoke). 2003, Vol 22, Num 20, pp 3188-3192, issn 0950-9232, 5 p.Article

Design of clinical trials for therapeutic cancer vaccines developmentMACKIEWICZ, Jacek; MACKIEWICZ, Andrzej.European journal of pharmacology. 2009, Vol 625, Num 1-3, pp 84-89, issn 0014-2999, 6 p.Article

Cancer Immunotherapy and Nanomedicine : Nanomedecine for Cancer TherapySHENG, Wei-Yun; HUANG, Leaf.Pharmaceutical research. 2011, Vol 28, Num 2, pp 200-214, issn 0724-8741, 15 p.Article

Exosomes as Immunotheranostic Nanoparticles : EXTRACELLULAR EXOSOMES AND MICROVESICLES IN ALLERGIC AND IMMUNOLOGICAL DISEASESNATASHA, G; GUNDOGAN, Buket; AARON TAN et al.Clinical therapeutics. 2014, Vol 36, Num 6, pp 820-829, issn 0149-2918, 10 p.Article

Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and marketHUANG, Chung-Jr; LOWE, Adam J; BATT, Carl A et al.Applied microbiology and biotechnology. 2010, Vol 87, Num 2, pp 401-410, issn 0175-7598, 10 p.Article

Potential of tumour cells for delivering oncolytic virusesRAYKOV, Z; ROMMELAERE, J.Gene therapy (Basingstoke). 2008, Vol 15, Num 10, pp 704-710, issn 0969-7128, 7 p.Article

An overview of targeted treatments in cancerABOU-JAWDE, Rony; CHOUEIRI, Toni; ALEMANY, Carlos et al.Clinical therapeutics. 2003, Vol 25, Num 8, pp 2121-2137, issn 0149-2918, 17 p.Article

Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimenMOCHIZUKI, Kazuo; SATO, Yuji; TODO, Satoru et al.International journal of oncology. 2004, Vol 25, Num 1, pp 121-131, issn 1019-6439, 11 p.Article

Cancer vaccine characterization: From bench to clinicDE LA LUZ-HERNANDEZ, K; RABASA, Y; MONTESINOS, R et al.Vaccine. 2014, Vol 32, Num 24, pp 2851-2858, issn 0264-410X, 8 p.Conference Paper

ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccinesSTEWART, Trina J; DRANE, Debbie; MALLIAROS, Jim et al.Vaccine. 2004, Vol 22, Num 27-28, pp 3738-3743, issn 0264-410X, 6 p.Article

Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicityGATHURU, John K; KOIDE, Fusataka; RAGUPATHI, Govind et al.Vaccine. 2005, Vol 23, Num 39, pp 4727-4733, issn 0264-410X, 7 p.Article

Prophylactic cancer vaccination by targeting functional non-selfTUOHY, Vincent K; RITIKA JAINI.Annals of medicine (Helsinki). 2011, Vol 43, Num 5-6, pp 356-365, issn 0785-3890, 10 p.Article

A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell LymphomaKOC, Omer N; REDFERN, Charles; WIERNIK, Peter H et al.Journal of immunotherapy (1997). 2010, Vol 33, Num 2, pp 178-184, issn 1524-9557, 7 p.Article

Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4⁺ T-cell Responses in Patients With Advanced HCCGREEN, Tim F; ORMANDY, Lars A; FIKUART, Annika et al.Journal of immunotherapy (1997). 2010, Vol 33, Num 2, pp 211-218, issn 1524-9557, 8 p.Article

MHC II lung cancer vaccines prime and boost tumor-specific CD4⁺ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cellsSRIVASTAVA, Minu K; BOSCH, Jacobus J; WILSON, Ashley L et al.International journal of cancer (Print). 2010, Vol 127, Num 11, pp 2612-2621, issn 0020-7136, 10 p.Article

A Novel Mouse Model for Evaluation and Prediction of HLA-A2-restricted CEA Cancer Vaccine ResponsesCONFORTI, Antonella; PERUZZI, Daniela; GIANNETTI, Patrizia et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 7, pp 744-754, issn 1524-9557, 11 p.Article

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiformeIZUMOTO, Shuichi; TSUBOI, Akihiro; KAWAKAMI, Manabu et al.Journal of neurosurgery. 2008, Vol 108, Num 5, pp 963-971, issn 0022-3085, 9 p.Article

Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) : A Phase 2 TrialAMATO, Robert J; DRURY, Noel; NAYLOR, Stuart et al.Journal of immunotherapy (1997). 2008, Vol 31, Num 6, pp 577-585, issn 1524-9557, 9 p.Article

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patientsKAWABATA, Ryohei; WADA, Hisashi; KUMON, Hiromi et al.International journal of cancer. 2007, Vol 120, Num 10, pp 2178-2184, issn 0020-7136, 7 p.Article

Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primatesAURISICCHIO, Luigi; MENNUNI, Carmela; GIANNETTI, Patrizia et al.International journal of cancer. 2007, Vol 120, Num 11, pp 2290-2300, issn 0020-7136, 11 p.Article

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24⁺ HRPC patientsNOGUCHI, Masanori; ITOH, Kyogo; YAO, Akihisa et al.The Prostate. 2005, Vol 63, Num 1, pp 1-12, issn 0270-4137, 12 p.Article

Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patientHARADA, Mamoru; MATSUEDA, Satoko; YAO, Akihisa et al.Journal of immunotherapy (1997). 2005, Vol 28, Num 4, pp 368-375, issn 1524-9557, 8 p.Article

Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysateITO, Akira; FUJIOKA, Masatake; TANAKA, Kouji et al.Journal of bioscience and bioengineering. 2005, Vol 100, Num 1, pp 36-42, issn 1389-1723, 7 p.Article

Immunosenescence and cancer vaccines : Imapct of aging on cancer immunity and immunotherapyPROVINCIALI, Mauro.Cancer immunology and immunotherapy. 2009, Vol 58, Num 12, pp 1959-1967, issn 0340-7004, 9 p.Article

Future directions for vaccine-based therapies : The status of cancer vaccine therapies in urologyVIEWEG, Johannes.Urologic oncology. 2006, Vol 24, Num 5, pp 448-455, issn 1078-1439, 8 p.Article